

In the claims:

1. **(Previously amended)** A method of selecting a treatment for an immune-mediated disorder having an inflammatory component and/or a cellular hyperproliferation component, comprising identifying the presence of one or both of said components; and selecting at least one corticosteroid which interacts with a gold compound to exhibit preferential synergistic action towards the one components of said disorder if only one component is present or to exhibit equal action towards each component of said disorder if both components are present.
2. **(Previously amended)** A method according to claim 1, wherein the disorder has an inflammatory component and a cellular hyperproliferation component.
3. **(Previously amended)** A method according to claim 1, wherein the gold compound and the at least one corticosteroid are administered simultaneously.
4. **(Previously amended)** A method according to claim 1, wherein the gold compound and the at least one corticosteroid are administered sequentially.
5. **(Previously amended)** A method according to claim 4, wherein the at least one corticosteroid is administered after the gold compound.
6. **(Previously amended)** A method according to claim 1, comprising selecting at least two corticosteroids, at least one of which is selected to interact with the gold compound to exhibit preferential synergistic action towards the inflammatory component, and at least another is selected to interact with the gold compound to exhibit preferential synergistic action towards the cellular hyperproliferation component of said disorder.

7. **(Original)** A method according to claim 1, wherein the disorder is an immune-mediated dermatological disorder.
8. **(Original)** A method according to claim 7, wherein the disorder is psoriasis.
9. **(Original)** A method according to claim 7, wherein the disorder is dermatitis.
10. **(Original)** A method according to claim 1, wherein the disorder is rheumatoid arthritis.
11. **(Original)** A method according to claim 1, wherein the gold compound is lipid soluble.
12. **(Original)** A method according to claim 1, wherein the at least one corticosteroid is selected to interact with the gold compound to exhibit synergistic activity towards cellular hyperproliferation in preference to inflammation.
13. **(Original)** A method according to claim 12, wherein the at least one corticosteroid is selected from the group consisting of betamethasone dipropionate, fluocinolone acetonide and hydrocortisone.
14. **(Original)** A method according to claim 1, wherein the at least one corticosteroid is selected to interact with the gold compound to exhibit synergistic activity towards inflammation in preference to cellular hyperproliferation.
15. **(Original)** A method according to claim 14, wherein the at least one corticosteroid is selected from the group consisting of betamethasone dipropionate, fluocinolone acetonide and mometasone furoate.

16. **(Original)** A method according to claim 10, wherein the corticosteroid is selected from the group consisting of hydrocortisone acetate, hydrocortisone, betamethasone, betamethasone dipropionate, dexamethasone, fluocortolone 21-privalate, triamcinolone acetonide, betamethasone valerate, alclometasone dipropionate, halcinonide, mometasone furoate and fluocinolone acetonide.

17. **(Original)** A method according to claim 16, wherein the corticosteroid is selected from the group consisting of hydrocortisone, betamethasone dipropionate, mometasone furoate and fluocinolone acetonide.

18. **(Original)** A method according to claim 1, wherein the gold compound is auranofin.

19. **(Original)** A method according to claim 1, wherein the gold compound is administered systemically.

20. **(Original)** A method according to claim 1, wherein the gold compound is administered orally.

21. **(Original)** A method according to claim 1, wherein the gold compound is administered locally.

22. **(Original)** A method according to claim 1, wherein the gold compound is administered topically.

23. **(Original)** A method according to claim 1, wherein the gold compound is administered by intra-articular injection.

24. **(Original)** A method according to claim 1, wherein the at least one corticosteroid is administered systemically.

25. **(Original)** A method according to claim 1, wherein the at least one corticosteroid is administered orally.

26. **(Original)** A method according to claim 1, wherein the at least one corticosteroid is administered locally.

27. **(Original)** A method according to claim 1, wherein the at least one corticosteroid is administered topically.

28. **(Original)** A method according to claim 1, wherein the at least one corticosteroid is administered by intra-articular injection.

29. **(Previously amended)** A pharmaceutical composition selected according to the method of claim 1, in combination with a pharmaceutically acceptable carrier, excipient, adjuvant or solvent.

30. **(Original)** A pharmaceutical composition according to claim 29, wherein the composition is formulated for systemic administration.

31. **(Original)** A pharmaceutical composition according to claim 29, wherein the composition is formulated for oral administration.

32. **(Original)** A pharmaceutical composition according to claim 29, wherein the composition is formulated for local administration.

33. **(Original)** A pharmaceutical composition according to claim 29, wherein the composition is formulated for topical administration.

34. **(Original)** A pharmaceutical composition according to claim 29, wherein the composition is formulated for administration by intra-articular injection.

35. **(Original)** A pharmaceutical composition according to claim 29, wherein the corticosteroid is selected from the group consisting of hydrocortisone acetate, hydrocortisone, betamethasone, betamethasone dipropionate, dexamethasone, fluocortolone 21-privalate, triamcinolone acetonide, betamethasone valerate, alclometasone dipropionate, halcinonide, mometasone furoate and fluocinolone acetonide.

36. **(Previously Amended)** A pharmaceutical composition according to claim 35 wherein the corticosteroid is selected from the group consisting of hydrocortisone, betamethasone dipropionate, mometasone furoate and fluocinolone acetonide.

37. **(Previously Amended)** A pharmaceutical composition according to claim 29, wherein the gold compound is auranofin.

38. **(Previously added)** A method of treating an immune-mediated disorder comprising administering to a patient in need of such treatment a pharmaceutical composition according to claim 29.

✓
Please add new claims 39-46 as follows:

39. **(New)** A pharmaceutical composition comprising a gold compound and one or more corticosteroids selected from the group consisting of fluocinolone acetonide (FA) and mometasone furoate (MMF) in combination with a pharmaceutically acceptable carrier, excipient, adjuvant or solvent.

40. **(New)** The pharmaceutical composition according to claim 39, wherein the gold compound is auranofin.

41. (New) The pharmaceutical composition according to claim 39, wherein the composition is formulated for administration by a route selected from the group consisting of systemic administration, oral administration, local administration, topical administration, and intra-articular injection.

42. (New) A method of treating an immune-mediated disorder comprising administering to a patient in need of such treatment the pharmaceutical composition of claim 39.

43. (New) The method according to claim 42, wherein the patient is suffering from an immune-mediated disorder characterized by inflammation.

44. (New) The method according to claim 42, wherein the patient is suffering from an immune-mediated disorder characterized by cell hyperproliferation.

45. (New) A method according to claim 42, wherein the gold compound and the one or more corticosteroids are administered simultaneously.

46. (New) A method according to claim 42, wherein the gold compound and the one or more corticosteroids are administered sequentially.
